This is a community-generated profile. If you would like to claim it, please .
DiscoverStartupsAsklepios BioPharmaceutical
Asklepios BioPharmaceutical company logo
AAV gene therapies for diseases501-1000 Employees

Asklepios BioPharmaceutical careers

AAV gene therapies for diseases
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders and other rare diseases. It offers proprietary AAV technology, manufacturing capabilities, and a robust pipeline of in-house clinical programs for clients in the medical biopharmaceutical industry. Its pipeline includes clinical-stage programs in Pompe disease and congestive heart failure and a diverse preclinical portfolio of therapeutics targeting neuromuscular, CNS, and other diseases, as well as out-licensed clinical indications for hemophilia and Duchenne muscular dystrophy. The company’s gene therapy platform includes Pro10, an industry-leading proprietary cell line manufacturing process, and an extensive AAV capsid, and promoter library. Asklepios BioPharmaceutical was founded in 2001 and is headquartered in Research Triangle Park, North Carolina.

Manager, Data Management

Remote only • United States
yesterday

Director, AI Automation and Integration

In office • Durham • Philadelphia
3 weeks ago
3 months ago
Valuation

$2B

Funded over

1 round

Latest round

Seed (Oct 2020)